The recently published SOLOIST‐WHF (Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure) trial studied the effects of sotagliflozin (a combined SGLT2/SGLT1 inhibitor) in a population comprising both patients with HFrEF and patients with HF and preserved ejection fraction (HFpEF).8 Here, SLC5A2 is linked to heart failure.